Rocket, putting regulatory roadblocks in its rearview, receives show of confidence in gene therapy from FDA February 7, 2023 6:00 am https://www.fiercebiotech.com/biotech/rocket-putting-regulatory-wrangles-its-rearview-receives-show-confidence-gene-therapy-fda

Investor Syncona blames bear market's ravaging of British biotechs for ‘disappointing’ returns February 7, 2023 5:47 am https://www.fiercebiotech.com/biotech/investor-syncona-blames-bear-markets-ravaging-british-biotechs-disappointing-returns

Roche races to regulators after matching AstraZeneca’s rare disease blockbuster in phase 3 February 7, 2023 1:59 am https://www.fiercebiotech.com/biotech/roche-races-regulators-after-matching-astrazenecas-rare-disease-blockbuster-phase-3

Do we need new Alzheimer's scales, or a new perspective on what's meaningful to patients? February 6, 2023 10:56 am https://www.fiercebiotech.com/biotech/do-we-need-new-alzheimers-scales-or-new-perspective

Cell therapy biotech lays off 25% of staff citing difficult funding environment February 6, 2023 9:22 am https://www.fiercebiotech.com/biotech/cell-therapy-biotech-lays-25-staff-cites-difficult-funding-environment-reason-behind-cuts

BMS returns $475M IL-12 oncology asset to Dragonfly’s pond February 6, 2023 6:38 am https://www.fiercebiotech.com/biotech/bms-returns-475m-oncology-asset-back-dragonflys-pond

GSK's retrospective trial diversity study shows there's more work to do February 6, 2023 5:42 am https://www.fiercebiotech.com/biotech/gsks-retrospective-trial-diversity-study-shows-theres-more-work-do

J&J's latest data for nipocalimab in fetal disorder suggests Momenta acquisition may still pay off February 6, 2023 5:22 am https://www.fiercebiotech.com/biotech/jj-latest-data-nipocalimab-fetal-disorder-suggests-momenta-buy-may-pay

Boarding priority review track, Biogen and Sage get August decision date for depression drug approval February 6, 2023 3:10 am https://www.fiercebiotech.com/biotech/boarding-priority-review-track-biogen-and-sage-get-august-pdufa-date-oral-depression-drug

Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3 February 6, 2023 2:01 am https://www.fiercebiotech.com/biotech/ex-shire-drug-improves-outcomes-autoimmune-disease-setting-certa-path-phase-3